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Background
The SCOT colorectal cancer trial is a phase III rando-
mised controlled, multi-centre, non-inferiority trial com-
paring the efficacy of 12 weeks of chemotherapy versus
24 weeks and the associated toxicity, along with a life-
time economic analysis. The economic analysis will use
prospective trial data to inform a lifetime cost-effective-
ness model.
Quality of life and toxicity data are only collected in a
proportion of patients as the sample size required for
these comparisons is much smaller than that required to
show a significant difference in efficacy. This paper
reports on an analysis of adverse events (AEs) and qual-
ity of life data, undertaken to determine whether it was
appropriate to stop collecting quality of life data from
new recruits. Do we have a large enough sample to
detect whether the AEs and severity of AEs impact on
quality of life?
Methods
Statistical analysis of data from the SCOT trial of
patients with fully resected stage III colorectal cancer or
fully resected high-risk stage II disease. Data collection
commenced June 2008. EQ-5D and AE data was
recorded at baseline, each treatment cycle and at follow-
up intervals until December 2010. This interim dataset
was analysed in STATA, using univariate and multivari-
ate regression.
Results
Univariate analysis showed that the majority of AEs sig-
nificantly reduce quality of life (significant at 3% or
less); however, multivariate analysis was inconclusive as
AEs were highly correlated with one another. Uni- and
multivariate regressions were re-run using indicator
variables for AE grade groups for each specific adverse
event type, and showed a highly significant (1% level)
negative impact on quality of life as severity of grade
increased, particularly for the adverse events Diarrhoea
(-0.04 grade 1/2, -0.09 grade 3/4), Fatigue (-0.02 grade
1/2), Nausea (-0.05 grade 1/2, -0.14 grade 3/4), Neuro-
pathy sensory (-0.02 grade 1/2, -0.19 grade 3/4), and
Vomiting (-0.05 grade 1/2). Quality of life had a signifi-
cant negative relationship with severity of AE grade,
regardless of the specific event (0.017 grade 1, -0.058
grade 2, -0.062 grade 3, -0.145 grade 4).
Conclusions
Adverse events impact negatively on quality of life; how-
ever, multivariate regression was inconclusive due to
multicolinearity between the adverse events. There was
strong evidence to show that the AEs and AE grades
significantly reduced quality of life using univariate ana-
lysis and therefore we can be confident that the sample
from June 2008-Dec 2010 is sufficient and can stop col-
lecting such data from new recruits.
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